CRUCELL TO LICENSE PER.C6 CELL LINE TECHNOLOGY TO VAKZINE PROJEKT MANAGEMENT

Crucell NV said it has agreed to license its PER.C6 human cell-line technology to German vaccine development company Vakzine Projekt Management (VPM) GmbH for use in the development of a vaccine to prevent a specific but undisclosed infectious disease, and to develop diagnostics. Under the terms of the agreement, Crucell will receive a research license fee and annual maintenance fees. Further financial details were not disclosed.

Forbes (http://www.forbes.com/business/feeds/afx/2005/12/08/afx2377310.html)